632 related articles for article (PubMed ID: 9787370)
61. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
62. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group.
Strahlman ER; Vogel R; Tipping R; Clineschmidt CM
Ophthalmology; 1996 Aug; 103(8):1283-93. PubMed ID: 8764800
[TBL] [Abstract][Full Text] [Related]
63. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
Watson P; Stjernschantz J
Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
[TBL] [Abstract][Full Text] [Related]
64. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
65. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
Oztürk F; Ermiş SS; Inan UU; Aşagidag A; Yaman S
J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
[TBL] [Abstract][Full Text] [Related]
66. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
67. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Lee DA; Gornbein JA
J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
[TBL] [Abstract][Full Text] [Related]
68. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
69. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
[TBL] [Abstract][Full Text] [Related]
70. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
[TBL] [Abstract][Full Text] [Related]
71. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.
Loon SC; Liew G; Fung A; Reid SE; Craig JC
Clin Exp Ophthalmol; 2008 Apr; 36(3):281-9. PubMed ID: 18412600
[TBL] [Abstract][Full Text] [Related]
72. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
[TBL] [Abstract][Full Text] [Related]
73. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
74. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
Mishima HK; Masuda K; Kitazawa Y; Azuma I; Araie M
Arch Ophthalmol; 1996 Aug; 114(8):929-32. PubMed ID: 8694726
[TBL] [Abstract][Full Text] [Related]
75. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
76. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
March WF; Ochsner KI
Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
[TBL] [Abstract][Full Text] [Related]
77. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
Heijl A; Strahlman E; Sverrisson T; Brinchman-Hansen O; Puustjärvi T; Tipping R
Ophthalmology; 1997 Jan; 104(1):137-42. PubMed ID: 9022118
[TBL] [Abstract][Full Text] [Related]
78. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
79. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
Cantor LB
Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518
[TBL] [Abstract][Full Text] [Related]
80. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
